Skip to main content
SpringerLink
Log in

Mögliche Komplikationen bei der Nachsorge

Lungentransplantation

  • zertifizierte fortbildung
  • Published:
Pneumo News Aims and scope

Zusammenfassung

Die Lungentransplantation (LuTX) ist eine Therapiemöglichkeit für Patienten mit terminalen Lungenerkrankungen. Primäres Organversagen, Infektionen, zelluläre und humorale Abstoßungsreaktionen, lymphozytische Bronchiolitis sowie die chronische Abstoßungsreaktion mit ihren Phänotypen Bronchiolitis-obliterans-Syndrom und restriktivem Allograft-Syndrom (RAS) sind inzwischen gut charakterisierte Komplikationen nach LuTX und Ursache für Erkrankungen und Mortalität.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2
3

Literatur

  1. Benden C, Edwards LB, Kucheryavaya AY et al (2013) The Registry of the International Society for Heart and Lung Transplantation: sixteenth official pediatric lung and heart-lung transplantation report — 2013; focus theme: age. J Heart Lung Transplant 32:989–997

    Article  PubMed  Google Scholar 

  2. Christie JD, Edwards LB, Kucheryavaya AY et al (2012) The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report — 2012. J Heart Lung Transplant 31:1073–1086

    Article  PubMed  Google Scholar 

  3. Treede H, Glanville AR, Klepetko W et al (2012) Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transplant 31:797–804

    Article  PubMed  Google Scholar 

  4. Gullestad L, Mortensen SA, Eiskjaer H et al (2010) Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation 90:1581–1589

    Article  PubMed  CAS  Google Scholar 

  5. Bhorade S, Ahya VN, Baz MA et al (2011) Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation. Am J Respir Crit Care Med 183:379–387

    Article  PubMed  CAS  Google Scholar 

  6. Euvrard S, Morelon E, Rostaing L et al (2012) Sirolimus and secondary skincancer prevention in kidney transplantation. N Engl J Med 367:329–339

    Article  PubMed  CAS  Google Scholar 

  7. Hillen U, Griewank K, Sommerwerck U et al (2013) Tumor regression and sirolimus-based therapy in lung transplantation. J Heart Lung Transplant 32:938–939

    Article  PubMed  Google Scholar 

  8. Christie JD, Edwards LB, Kucheryavaya AY et al (2011) The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report — 2011. J Heart Lung Transplant 30:1104–1122

    Article  PubMed  Google Scholar 

  9. Jaksch P, Wiedemann D, Augustin V et al (2013) Antithymocyte globulin induction therapy improves survival in lung transplantation for cystic fibrosis. Transpl Int 26:34–41

    Article  PubMed  CAS  Google Scholar 

  10. Gupta D, Agarwal R, Aggarwal AN et al (2012) Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: joint ICS/NCCP(I) recommendations. Lung India 29:S27–S62

    Article  PubMed  PubMed Central  Google Scholar 

  11. Palmer SM, Limaye AP, Banks M et al (2010) Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 152:761–769

    Article  PubMed  Google Scholar 

  12. Schlischewsky E, Fuehner T, Warnecke G et al (2013) Clinical significance of quantitative cytomegalovirus detection in bronchoalveolar lavage fluid in lung transplant recipients. Transpl Infect Dis 15:60–69

    Article  PubMed  CAS  Google Scholar 

  13. Snydman DR, Limaye AP, Potena L, Zamora MR (2011) Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc 43:S1–S17

    Article  PubMed  Google Scholar 

  14. Kotton CN, Kumar D, Caliendo AM et al (2010) International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89:779–795

    Article  PubMed  Google Scholar 

  15. Ruhnke M, Rickerts V, Cornely OA et al (2011) Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for chemotherapy. Mycoses 54:279–310

    Article  PubMed  CAS  Google Scholar 

  16. Lewis RE, Viale P, Kontoyiannis DP (2012) The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida. Virulence 3:368–376

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kourkoumpetis TK, Desalermos A, Muhammed M, Mylonakis E (2012) Central nervous system aspergillosis: a series of 14 cases from a general hospital and review of 123 cases from the literature. Medicine (Baltimore) 91:328–336

    Article  Google Scholar 

  18. Beirao F, Araujo R (2013) State of the art diagnostic of mold diseases: a practical guide for clinicians. Eur J Clin Microbiol Infect Dis 32:3–9

    Article  PubMed  CAS  Google Scholar 

  19. Porhownik NR (2013) Airway complications post lung transplantation. Curr Opin Pulm Med 19:174–180

    Article  PubMed  Google Scholar 

  20. Lischke R, Pozniak J, Vondrys D, Elliott MJ (2011) Novel biodegradable stents in the treatment of bronchial stenosis after lung transplantation. Eur J Cardiothorac Surg 40:619–624

    PubMed  Google Scholar 

  21. Gottlieb J, Fuehner T, Dierich M et al (2009) Are metallic stents really safe? A long-term analysis in lung transplant recipients. Eur Respir J 34:1417–1422

    Article  PubMed  CAS  Google Scholar 

  22. Sundset A, Lund MB, Hansen G et al (2012) Airway complications after lung transplantation: long-term outcome of silicone stenting. Respiration 83:245–252

    Article  PubMed  CAS  Google Scholar 

  23. Gordon IO, Bhorade S, Vigneswaran WT et al (2012) SaLUTaRy: survey of lung transplant rejection. J Heart Lung Transplant 31:972–979

    Article  PubMed  Google Scholar 

  24. Greenland JR, Jones KD, Hays SR et al (2013) Association of large-airway lymphocytic bronchitis with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 187:417–423

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Tait BD, Susal C, Gebel HM et al (2013) Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 95:19–47

    Article  PubMed  CAS  Google Scholar 

  26. Yabu JM, Higgins JP, Chen G et al (2011) C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 91:342–347

    Article  PubMed  CAS  Google Scholar 

  27. Chin C, Chen G, Sequeria F et al (2011) Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 30:158–163

    Article  PubMed  Google Scholar 

  28. Berry G, Burke M, Andersen C et al (2013) Pathology of pulmonary antibody- mediated rejection: 2012 update from the Pathology Council of the ISHLT. J Heart Lung Transplant 32:14–21

    Article  PubMed  Google Scholar 

  29. Yousem SA, Zeevi A (2012) The histopathology of lung allograft dysfunction associated with the development of donor-specific HLA alloantibodies. Am J Surg Pathol 36:987–992

    Article  PubMed  Google Scholar 

  30. Hachem RR, Yusen RD, Meyers BF et al (2010) Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 29:973–980

    Article  PubMed  PubMed Central  Google Scholar 

  31. Lobo LJ, Aris RM, Schmitz J, Neuringer IP (2013) Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant 32:70–77

    Article  PubMed  Google Scholar 

  32. Snyder LD, Wang Z, Chen DF et al (2013) Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. Chest 144:226–233

    Article  PubMed  PubMed Central  Google Scholar 

  33. Roberts DM, Jiang SH, Chadban SJ (2012) The treatment of acute antibody- mediated rejection in kidney transplant recipients — a systematic review. Transplantation 94:775–783

    Article  PubMed  CAS  Google Scholar 

  34. Lemy A, Toungouz M, Abramowicz D (2010) Bortezomib: a new player in pre- and post-transplant desensitization? Nephrol Dial Transplant 25:3480–3489

    Article  PubMed  CAS  Google Scholar 

  35. Woodle ES, Alloway RR, Girnita A (2011) Proteasome inhibitor treatment of antibody-mediated allograft rejection. Curr Opin Organ Transplant 16:434–438

    Article  PubMed  CAS  Google Scholar 

  36. Verleden GM, Vos R, Verleden SE et al (2011) Survival determinants in lung transplant patients with chronic allograft dysfunction. Transplantation 92:703–708

    Article  PubMed  Google Scholar 

  37. Vos R, Vanaudenaerde BM, Verleden SE et al (2011) A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 37:164–172

    Article  PubMed  CAS  Google Scholar 

  38. Finlen Copeland CA, Snyder LD, Zaas DW et al (2010) Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med 182:784–789

    Article  PubMed  PubMed Central  Google Scholar 

  39. Weigt SS, DerHovanessian A, Wallace WD et al (2013) Bronchiolitis obliterans syndrome: the Achilles’ heel of lung transplantation. Semin Respir Crit Care Med 34:336–351

    Article  PubMed  Google Scholar 

  40. Jaksch P, Scheed A, Keplinger M et al (2012) A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 31:950–957

    Article  PubMed  Google Scholar 

  41. Greer M, Dierich M, De Wall C et al (2013) Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. Am J Transplant 13:911–918

    Article  PubMed  CAS  Google Scholar 

  42. Sato M, Waddell TK, Wagnetz U et al (2011) Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant 30:735–742

    Article  PubMed  Google Scholar 

  43. Kohno M, Perch M, Andersen E et al (2011) Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation. Transplant Proc 43:1868–1870

    Article  PubMed  CAS  Google Scholar 

  44. Vanaudenaerde BM, Meyts I, Vos R et al (2008) A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 32:832–843

    Article  PubMed  CAS  Google Scholar 

  45. Verleden SE, Vandermeulen E, Ruttens D et al (2013) Neutrophilic reversible allograft dysfunction (NRAD) and restrictive allograft syndrome (RAS). Semin Respir Crit Care Med 34:352–360

    Article  PubMed  Google Scholar 

  46. Langer D, Burtin C, Schepers L et al (2012) Exercise training after lung transplantation improves participation in daily activity: a randomized controlled trial. Am J Transplant 12:1584–1592

    Article  PubMed  CAS  Google Scholar 

  47. DeNicola MM, Weigt SS, Belperio JA et al (2013) Pathologic findings in lung allografts with anti-HLA antibodies. J Heart Lung Transplant 32:326–332

    Article  PubMed  Google Scholar 

  48. Saini D, Weber J, Ramachandran S et al (2011) Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant 30:624–631

    Article  PubMed  PubMed Central  Google Scholar 

  49. Tiriveedhi V, Angaswamy N, Brand D et al (2012) A shift in the collagen V antigenic epitope leads to T helper phenotype switch and immune response to self-antigen leading to chronic lung allograft rejection. Clin Exp Immunol 167:158–168

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  50. Kastelijn EA, van Moorsel CH, Rijkers GT et al (2010) Polymorphisms in innate immunity genes associated with development of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant 29:665–671

    Article  PubMed  Google Scholar 

  51. Mertens V, Blondeau K, Van Oudenhove L et al (2011) Bile acids aspiration reduces survival in lung transplant recipients with BOS despite azithromycin. Am J Transplant 11:329–335

    Article  PubMed  CAS  Google Scholar 

  52. Paraskeva M, Bailey M, Levvey BJ et al (2011) Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 11:2190–2196

    Article  PubMed  CAS  Google Scholar 

  53. Kumar D, Husain S, Chen MH et al (2010) A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 89:1028–1033

    Article  PubMed  Google Scholar 

  54. Gottlieb J, Schulz TF, Welte T et al (2009) Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation 87:1530–1537

    Article  PubMed  Google Scholar 

  55. Gottlieb J, Mattner F, Weissbrodt H et al (2009) Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir Med 103:743–749

    Article  PubMed  CAS  Google Scholar 

  56. Weigt SS, Elashoff RM, Huang C et al (2009) Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 9:1903–1911

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abt. f. Pneumologie, Ruhrlandklinik, Westdeutsches Lungenzentrum, Universitätsklinikum Essen, Universität Duisburg-Essen, Essen, Deutschland

    Urte Sommerwerck, T. Rabis, P. Fleimisch & H. Teschler

  2. Abt. f. Thorakale Transplantation, Klinik für Thorax- und Kardiovaskuläre Chirurgie, Westdeutsches Herzzentrum, Universitätsklinikum Essen, Universität Duisburg-Essen, Essen, Deutschland

    H. Carstens & M. Kamler

  3. Abt. f. Pneumologie, Ruhrlandklinik, Westdeutsches Lungenzentrum, Universitätsklinikum Essen, Universität Duisburg-Essen, Tüschener Weg 40, 45239, Essen, Deutschland

    Urte Sommerwerck

Authors
  1. Urte Sommerwerck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Rabis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Fleimisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Carstens
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Teschler
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Kamler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Urte Sommerwerck.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Die Autoren legen folgende potenzielle Interessenkonflikte offen: keine. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sommerwerck, U., Rabis, T., Fleimisch, P. et al. Mögliche Komplikationen bei der Nachsorge. Pneumo News 6, 36–45 (2014). https://doi.org/10.1007/s15033-014-0001-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-014-0001-y

Search

Navigation